What does the evidence say about cannabis for inflammatory bowel disease? | Research

The takeaway

A scoping review of six studies (three RCTs and three observational) found some promising signals for cannabis in IBD, including improved well-being and reduced symptom scores, but evidence remains too limited for firm conclusions.

IBD patients curious about cannabis, and clinicians looking to understand the current evidence landscape for cannabinoid use in inflammatory bowel disease.

15-40% of IBD patients use cannabis

What the researchers found

Studies reported improvements in general well-being and Harvey-Bradshaw Index, enhanced health perception scores (4.1 to 7.0, p=0.0002), weight gain, CDAI scores below 150, and reduced clinical complications. However, only six studies met inclusion criteria, highlighting the scarcity of evidence.

Why it matters

An estimated 15-40% of IBD patients already use cannabis for symptom management. Despite widespread patient interest, the evidence base remains remarkably thin, with only six studies meeting basic quality thresholds.

The numbers in context

15-40% of IBD patients use cannabis; 3 RCTs + 3 observational studies included; health perception improved from 4.1 to 7.0 (p=0.0002); CDAI target: below 150

How the study worked

Scoping review following PRISMA guidelines. Searched for studies assessing clinical remission in IBD patients using cannabis. Only three randomized controlled trials and three observational studies satisfied selection criteria.

What this study cannot tell us

Only six studies met inclusion criteria. Heterogeneous study designs, cannabis formulations, and outcome measures. No meta-analysis possible due to study variability.

How to read the evidence

Scoping review with only six included studies, heterogeneous designs, and no meta-analysis possible.

When this study was published

Published in 2021; additional trials may have been completed since.

The bigger picture

The gap between patient adoption and clinical evidence is striking. Many IBD patients are already using cannabis based on personal experience, but the research community has yet to produce the large-scale trials needed to guide clinical decisions.

Questions still open

What specific cannabis formulations and doses are most effective for IBD? Does cannabis work differently for Crohn's disease versus ulcerative colitis? Can cannabis achieve objective mucosal healing, not just symptom improvement?

Common questions

Does cannabis help with IBD?

Some studies report improved symptoms, well-being, and reduced complications, but the evidence base is too small (only 6 studies) to draw firm conclusions.

Why is there so little research?

Cannabis research has been limited by legal restrictions and funding barriers. The scoping review found that very few studies meet basic quality thresholds for studying cannabis in IBD.

What symptoms improved?

Studies reported improvements in general well-being, disease activity scores, health perception, weight gain, and reduced clinical complications, though results varied across studies.

Read the original research

Cannabis and Its Potential Protective Role Against Inflammatory Bowel Disease: A Scoping Review.

Cureus, 13(10), e18841

View on PubMed ↗Publisher’s paper ↗

Citation

Nso, Nso; Nyabera, Akwe; Nassar, Mahmoud; Alshamam, Mohsen S; Sumbly, Vikram; Vest, Mallorie; Patel, Nehal; Ojong, Gilbert; Rizzo, Vincent. (2021). Cannabis and Its Potential Protective Role Against Inflammatory Bowel Disease: A Scoping Review.. Cureus, 13(10), e18841. https://doi.org/10.7759/cureus.18841